Source: BMC Urology. Unidade: FM
Subjects: METALOPROTEINASES (REGULAÇÃO), NEOPLASIAS PROSTÁTICAS, PROGNÓSTICO, REAÇÃO EM CADEIA POR POLIMERASE, RNA POLIMERASES (ANÁLISE)
ABNT
REIS, Sabrina T et al. miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer. BMC Urology, v. 12, p. 6 , 2012Tradução . . Disponível em: https://doi.org/10.1186/1471-2490-12-14. Acesso em: 03 out. 2024.APA
Reis, S. T., Pontes-Junior, J., Antunes, A. A., Dall'Oglio, M. F., Dip, N., Passerotti, C. C., et al. (2012). miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer. BMC Urology, 12, 6 . doi:10.1186/1471-2490-12-14NLM
Reis ST, Pontes-Junior J, Antunes AA, Dall'Oglio MF, Dip N, Passerotti CC, Rossini GA, Morais DR, Nesrallah AJ, Piantino C, Srougi M, Leite KR. miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer [Internet]. BMC Urology. 2012 ; 12 6 .[citado 2024 out. 03 ] Available from: https://doi.org/10.1186/1471-2490-12-14Vancouver
Reis ST, Pontes-Junior J, Antunes AA, Dall'Oglio MF, Dip N, Passerotti CC, Rossini GA, Morais DR, Nesrallah AJ, Piantino C, Srougi M, Leite KR. miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer [Internet]. BMC Urology. 2012 ; 12 6 .[citado 2024 out. 03 ] Available from: https://doi.org/10.1186/1471-2490-12-14